SCHEMBL24140563

SCHEMBL24140563

COc1cc(-c2nc3cc(C4CCN(C)CC4)ccc3[nH]2)cc(O)c1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ QDPR P09417 3/20 0.53
▸ AMY1A P0DUB6 5/20 0.46
▸ KDM4E B2RXH2 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ BLM P54132 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ RXFP1 Q9HBX9 1/20 0.45
▸ TLR7 Q9NYK1 4/20 0.44
▸ TLR9 Q9NR96 3/20 0.44
▸ PARP1 P09874 2/20 0.41
▸ PARP2 Q9UGN5 1/20 0.41
▸ TGFBR1 P36897 1/20 0.41
▸ ACVR1 Q04771 1/20 0.41
▸ KCNH2 Q12809 1/20 0.41
▸ TLR8 Q9NR97 2/20 0.40
▸ SMPD3 Q9NY59 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24140543 0.89 AMY1A (0.49) AMY1AGAASMPD3NOX1
SCHEMBL24141227 0.89 AMY1A (0.48) AMY1AGAASMPD3NOX1
SCHEMBL30472053 0.88 QDPR (0.56) QDPRAMY1ATLR7TLR9TLR8
SCHEMBL24141203 0.88 QDPR (0.56) QDPRAMY1ATLR7TLR9TLR8
SCHEMBL30472012 0.88 AMY1A (0.47) QDPRAMY1ATLR7TLR9TGFBR1
SCHEMBL25316441 0.88 AMY1A (0.47) QDPRAMY1ATLR7TLR9TGFBR1
SCHEMBL30472059 0.82 KDM4E (0.47) AMY1AKDM4EMEN1ALDH1A1GAA
SCHEMBL24140523 0.82 KDM4E (0.47) AMY1AKDM4EMEN1ALDH1A1GAA
SCHEMBL24141174 0.82 ALDH1A1 (0.67) AMY1AKDM4EMEN1ALDH1A1GAA
SCHEMBL15837612 0.80 PARP1 (0.43) QDPRKDM4EALDH1A1SMN1; SMN2TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2023-07-27 — — US disclosed
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2023-07-27 — — US disclosed
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2023-07-27 — — US disclosed
WO-2021263079-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. (US) 2021-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF FEN1, ERCC4, DCLRE1B QDPR 2656/4885AMY1A 1386/4885KDM4E 2430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback